Ajax Therapeutics

0 followers


Ajax is targeting hematologic malignancies with greater precision by applying state-of-the-art computational chemistry and structural biology throughout the drug discovery and development process to create best-in-class therapies for significant unmet medical needs.

Industries

Employees

1-10

Links

Org chart

Martin Vogelbaum
Interim CEO

Martin Vogelbaum

Collapse
Craig E. Masse
SVP, Discovery Research
Alan Collis
SVP, Head of Preclinical Development
Christine Richardson
Senior Director, Program Management